Compounded medications are not FDA approved. FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed.

Is compounded tirzepatide FDA approved?

Released: · Last reviewed:

No. Compounded tirzepatide is not FDA approved. FDA approval applies to specific products — for tirzepatide, the approved products are Zepbound and Mounjaro — after review of manufacturing, safety, and effectiveness data. Compounded tirzepatide is prepared by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under compounding law, and FDA does not review compounded medications for safety, effectiveness, or quality before they are marketed. A compounded product is also not a "generic" of any approved product.

What compounded tirzepatide legally is

Compounding is the pharmacy practice of preparing a medication for a patient under a prescription. With the tirzepatide shortage resolved, mass-marketed compounded copies of approved products face significant federal restrictions, and compounded access generally depends on a prescriber documenting a patient-specific clinical need. Whether a particular prescription meets that standard is a case-specific medical and legal question this publication cannot decide.

What approval status means for evidence

The clinical trials behind Zepbound and Mounjaro studied those specific approved formulations. Their results do not automatically establish the potency, absorption, effectiveness, or safety of any compounded tirzepatide product — and evidence for injectable products never transfers to oral, ODT, sublingual, or troche formulations. See the safety guide for 503A vs 503B and the verification workflow before buying from any provider.

Frequently asked questions

Is compounded tirzepatide FDA-approved?

No. Compounded tirzepatide is not FDA-approved and is not a generic version of Zepbound or Mounjaro, and FDA does not review compounded drugs for safety, effectiveness or quality before they are sold, even when a state-licensed pharmacy prepares them for an individual prescription. FDA lists more than 730 adverse-event reports for compounded tirzepatide through May 31, 2026, and on September 18, 2026 it sent warning letter 738238 to Empower Pharmacy. FDA-approved Zepbound costs $299 to $449 a month through LillyDirect with refills within 45 days ($499 to $699 otherwise).